

Consolidated Financial Results For the 3rd Quarter Ended June 30, 2021  
Web Conference Q&A (held on July 30, 2021)

CMIC HOLDINGS Co., Ltd.

Q. Is significant performance growth of healthcare business in Q3 attributable to vaccination support? What is the future outlook of this business?

⇒Q3 Performance growth is attributable to the vaccination support with approx. 2 billion JPY sales impact. We expect the operation to continue until the beginning of the next fiscal year. Considering the delay in recording sales caused by the delay in vaccine supply, the performance impact in Q4 is forecasted conservatively.

Q. According to the full-year forecast that was announced today, it appears to have almost zero operating income for the sales of 22 billion JPY. Will you please tell me about the background of the forecast?

⇒Annual periodical maintenance is scheduled for CDMO business in Q4, and the impact of vaccination support was forecasted conservatively, and we are thinking of paying bonuses to our employees at the end of the fiscal year.

Q. Please tell me about the key market trends of the CRO industry, including the domestic market landscape and overseas activities.

⇒Though we have certain number of clinical trial projects in Japan, we see the trend of downsizing including the number of subjects. In addition, as the number of global trials is increasing, CMIC is further promoting globalization for both domestic and overseas projects as one of the critical action items in the mid-term plan.